• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Editorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19.社论:SARS-CoV-2 感染一年后出现的心血管并发症与潜在心血管危险因素或 COVID-19 的严重程度无关。
Med Sci Monit. 2022 May 1;28:e937048. doi: 10.12659/MSM.937048.
2
Long-term cardio-vascular risk assessment in chronic kidney disease and kidney transplanted patients following SARS-COV-2 disease: protocol for multi-center observational match controlled trial.SARS-CoV-2 疾病后慢性肾脏病和肾移植患者的长期心血管风险评估:多中心观察性匹配对照试验方案。
BMC Nephrol. 2022 May 6;23(1):176. doi: 10.1186/s12882-022-02809-4.
3
Acute and Post-Acute COVID-19 Cardiovascular Complications: A Comprehensive Review.急性和新冠病毒感染后心血管并发症:全面综述。
Cardiovasc Drugs Ther. 2024 Oct;38(5):1017-1032. doi: 10.1007/s10557-023-07465-w. Epub 2023 May 20.
4
Impact of Cardiovascular Risk Factors and Cardiovascular Diseases on Outcomes in Patients Hospitalized with COVID-19 in Daegu Metropolitan City.心血管危险因素和心血管疾病对大邱市 COVID-19 住院患者结局的影响。
J Korean Med Sci. 2021 Jan 11;36(2):e15. doi: 10.3346/jkms.2021.36.e15.
5
Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K.多病症模式与严重 SARS-CoV-2 感染风险:英国的一项观察性研究
BMC Infect Dis. 2021 Sep 4;21(1):908. doi: 10.1186/s12879-021-06600-y.
6
Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study.与 SARS-CoV-2 谱系 B.1.1.7 相关的在英国的死亡率和重症监护病房入院率:一项观察性队列研究。
Lancet Infect Dis. 2021 Nov;21(11):1518-1528. doi: 10.1016/S1473-3099(21)00318-2. Epub 2021 Jun 23.
7
An Overview on COVID-19 and its Effect on Cardiovascular Diseases.关于 COVID-19 及其对心血管疾病影响的概述。
Endocr Metab Immune Disord Drug Targets. 2021;21(11):1949-1953. doi: 10.2174/1871530321999201228214718.
8
Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities.生物信息学和系统生物学方法识别 COVID-19 对心血管和高血压合并症的影响。
Brief Bioinform. 2021 Mar 22;22(2):1387-1401. doi: 10.1093/bib/bbaa426.
9
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
10
Dynamic and features of SARS-CoV-2 infection in Gabon.加蓬的 SARS-CoV-2 感染的动态和特征。
Sci Rep. 2021 May 6;11(1):9672. doi: 10.1038/s41598-021-87043-y.

引用本文的文献

1
Long COVID or Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and the Urgent Need to Identify Diagnostic Biomarkers and Risk Factors.长新冠或 SARS-CoV-2 感染的后急性后遗症(PASC),以及迫切需要识别诊断生物标志物和风险因素。
Med Sci Monit. 2024 Sep 18;30:e946512. doi: 10.12659/MSM.946512.
2
Phenotypic switch of vascular smooth muscle cells in COVID-19: Role of cholesterol, calcium, and phosphate.新冠病毒肺炎中血管平滑肌细胞的表型转换:胆固醇、钙和磷酸盐的作用
J Cell Physiol. 2024 Dec;239(12):e31424. doi: 10.1002/jcp.31424. Epub 2024 Aug 26.
3
Editorial: Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). Updated Terminology for the Long-Term Effects of COVID-19.社论:严重急性呼吸综合征冠状病毒 2 感染的后遗症 (PASC)。COVID-19 长期影响的最新术语。
Med Sci Monit. 2023 Jul 1;29:e941595. doi: 10.12659/MSM.941595.

本文引用的文献

1
The COVID Heart-One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks.新冠之心——SARS-CoV-2感染一年后,患者面临一系列心血管风险增加的情况。
JAMA. 2022 Mar 22;327(12):1113-1114. doi: 10.1001/jama.2022.2411.
2
Heart-disease risk soars after COVID - even with a mild case.即使是轻症新冠感染后,心脏病风险也会飙升。
Nature. 2022 Feb;602(7898):560. doi: 10.1038/d41586-022-00403-0.
3
Clinical predictors of acute cardiac injury and normalization of troponin after hospital discharge from COVID-19.COVID-19 出院后急性心脏损伤和肌钙蛋白正常化的临床预测因子。
EBioMedicine. 2022 Feb;76:103821. doi: 10.1016/j.ebiom.2022.103821. Epub 2022 Feb 7.
4
Long-term cardiovascular outcomes of COVID-19.COVID-19 长期心血管后果。
Nat Med. 2022 Mar;28(3):583-590. doi: 10.1038/s41591-022-01689-3. Epub 2022 Feb 7.
5
Mechanisms of SARS-CoV-2 entry into cells.SARS-CoV-2 进入细胞的机制。
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20. doi: 10.1038/s41580-021-00418-x. Epub 2021 Oct 5.
6
Editorial: Long COVID, or Post-COVID Syndrome, and the Global Impact on Health Care.社论:长新冠,或新冠后综合征,以及其对全球医疗保健的影响。
Med Sci Monit. 2021 Jun 7;27:e933446. doi: 10.12659/MSM.933446.
7
Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.SARS-CoV-2 对心血管系统的影响:血管紧张素转换酶 2(ACE2)作为病毒受体和体内平衡调节剂的双重作用——综述。
Int J Mol Sci. 2021 Apr 26;22(9):4526. doi: 10.3390/ijms22094526.
8
Long COVID and chronic COVID syndromes.长期新冠和慢性新冠综合征。
J Med Virol. 2021 Mar;93(3):1242-1243. doi: 10.1002/jmv.26587. Epub 2020 Oct 30.
9
Myocyte-Specific Upregulation of in Cardiovascular Disease: Implications for SARS-CoV-2-Mediated Myocarditis.肌细胞特异性上调在心血管疾病中的作用:对 SARS-CoV-2 介导的心肌炎的影响。
Circulation. 2020 Aug 18;142(7):708-710. doi: 10.1161/CIRCULATIONAHA.120.047911. Epub 2020 Jun 22.

社论:SARS-CoV-2 感染一年后出现的心血管并发症与潜在心血管危险因素或 COVID-19 的严重程度无关。

Editorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19.

机构信息

Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA.

出版信息

Med Sci Monit. 2022 May 1;28:e937048. doi: 10.12659/MSM.937048.

DOI:10.12659/MSM.937048
PMID:35490309
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9069970/
Abstract

The consequences of SARS-CoV-2 infection include short-term, long-term, mild, and severe clinical symptoms. The cardiovascular system, including endothelial cells, vascular smooth muscle cells, and cardiac myocytes, are important targets for SARS-CoV-2. In February 2022, the findings from a large US cohort of individuals diagnosed with COVID-19 and two sets of control cohorts evaluated the risk and 12-month cardiovascular disease burden. Individuals who had COVID-19 had a 72% increased risk of heart failure, a 63% increased risk of myocardial infarction, and a 52% increased risk of ischemic stroke compared with controls. These results were independent of gender, race, age, and other cardiovascular risk factors, including diabetes, obesity, hypertension, hyperlipidemia, and chronic kidney disease. As of 25 April 2022, the World Health Organization (WHO) reported that more than 80 million people in the US, more than 22 million people in the UK, and more than 505 million people worldwide were infected with SARS-CoV-2. This Editorial aims to present what is currently known about the cardiovascular outcomes at one year following SARS-CoV-2 infection and highlights that primary care physicians should be mindful of the COVID-19 infection status of their patients when evaluating cardiovascular health.

摘要

SARS-CoV-2 感染的后果包括短期、长期、轻度和重度临床症状。心血管系统,包括内皮细胞、血管平滑肌细胞和心肌细胞,是 SARS-CoV-2 的重要靶标。2022 年 2 月,一项针对美国大量确诊 COVID-19 个体和两组对照组的研究结果评估了风险和 12 个月的心血管疾病负担。与对照组相比,患有 COVID-19 的个体心力衰竭风险增加 72%,心肌梗死风险增加 63%,缺血性中风风险增加 52%。这些结果独立于性别、种族、年龄和其他心血管危险因素,包括糖尿病、肥胖、高血压、高血脂和慢性肾脏病。截至 2022 年 4 月 25 日,世界卫生组织(WHO)报告称,美国有超过 8000 万人、英国有超过 2200 万人、全球有超过 5.05 亿人感染了 SARS-CoV-2。本社论旨在介绍目前已知的 SARS-CoV-2 感染后一年的心血管结局,并强调初级保健医生在评估心血管健康时应注意患者的 COVID-19 感染状况。